Ultragenyx Pharmaceutical (RARE) Short-term Investments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Short-term Investments data on file, last reported at $238.0 million in Q1 2026.

• On a quarterly basis, Short-term Investments fell 35.22% year-over-year to $238.0 million in Q1 2026; TTM through Mar 2026 was $238.0 million, a 35.22% decrease from a year earlier, with the FY2025 full-year figure at $259.0 million, down 40.6% from the prior year.
• Short-term Investments for Q1 2026 stood at $238.0 million, down from $259.0 million in the prior quarter.
• Over the last five years, Short-term Investments for RARE reached as high as $543.6 million in Q1 2023 and fell as low as $2.8 million in Q4 2022.
• Historically, Short-term Investments has averaged $328.3 million across 5 years, with a median of $367.4 million in 2025.
• Across the five-year window, Short-term Investments tumbled 84.83% in 2022 and surged 13507.99% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $2.8 million in 2022, then gained by 14.14% to $3.2 million in 2023, then jumped by 13507.99% to $436.0 million in 2024, then tumbled by 40.6% to $259.0 million in 2025, then dropped by 8.11% to $238.0 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $238.0 million in Q1 2026, $259.0 million in Q4 2025, and $222.7 million in Q3 2025.